Why Judy Faulkner rejects the MBA mindset

At Forbes Healthcare Summit, Epic CEO Judy Faulkner explained why the company's long-protected independence and unconventional management approach have been central to its dominance as an EHR vendor. Now, she says the company's future will depends on how it uses its massive data stores to support AI-powered clinical decisions.

Editor's Pick

Top Story Why Epic's Judy Faulkner Rejects the MBA Mindset At Forbes Healthcare Summit, Epic CEO Judy Faulkner explained why the company's long-protected independence and unconventional management approach have been central to its dominance as an EHR vendor. Now, she says the company's future will depends on how it uses its massive data stores to support AI-powered clinical decisions. Sponsored The Massive AI Potential Hiding in Your RCM Software Presented by Smarter Technologies A new report, reveals exactly what 125 medical billing professionals—from CFOs to billing managers—think about their current Revenue Cycle Management (RCM) software and the massive potential of AI. Over 90% of respondents want AI-driven solutions.  Click here to see the full results.

Featured News

Relapses Don't 'Happen in Clinics': Empathy Health Technologies Secures $7.6M for Sobriety App Empathy Health's $7.6 million round was led by HealthX Ventures and included participation from Nina Capital, Ikigai Healthcare Funds, American Heart Association Ventures, Suncoast Ventures, Cortado Ventures and Wilson Sonsini Investment Company. Debunked Episode 22: With ACA Subsidies Set to Expire and the Open Enrollment Window Closing, Members of Congress Brainstorm Alternatives What are the alternatives to extending ACA subsidies for the 22 million people who purchase health plans on the ACA Marketplace? That's the focus of the latest episode of the Debunked podcast, hosted by MedCity News Editor-in-Chief Arundhati Parmar and Samir Batra, managing partner of Health Innovation Pitch. Crescent Bio Expands Its Cancer Drug Combo Ambitions With New Kelun-Biotech Alliance Crescent Biopharma gains rights to a Kelun-Biotech antibody drug conjugate it plans to test in combination with its lead cancer drug, a bispecific antibody designed to block PD-1 and VEGF. Separately, Crescent raised $185 million in a private placement to support its clinical trial plans. Building Smarter, Safer Healthcare: The Role of Tech Partners in AI Adoption Tech partners play an important role in scaling AI effectively and responsibly – without compromising patient trust. Modern Interoperability: How APIs Can Heal a Fragmented System The go-to mechanisms for differential payment – network design, case management, quality measurement and prior authorization – increasingly rely on APIs capable of handling not only claims data but, more importantly, the clinical data critical to intelligent decision-making.

Video   What Are Investors Looking For In Mental Health Startups? At a recent behavioral health tech conference, Emily Durfee, a partner at Healthworx Ventures, shared her thoughts on how to differentiate mental health startups in an increasingly crowded market. She said it's important to figure out if the startup is solving a key problem for their customer — whether that's a provider, payer, employer or consumer.

Sponsored As Healthcare and Biopharma Companies Embrace AI, Insurance Underwriters See Risks and Opportunities Presented by Munich Re Specialty – North America In an interview, Munich Re Specialty Senior Vice President Jim Craig talked about the risk that accompanies innovation and the important role that insurers play. Learn More

Resources

MedCity Pivot Podcast: Could This Device Make Managing Brain Health Easier? Dr. Iftach Dolev, a neuroscientist and CEO of QuantalX, explained how his company's new FDA-cleared de novo device can bring a powerful tool to psychiatrists and neurologists alike. He claims this marks an important moment for brain health. View Now

MedCity News • PO Box 901 • New York, NY unsubscribe